Lymphoma
AUGMENT trial - Lenalidomide + Rituximab PFS
In phase III AUGMENT trial presented by Dr. John Leonard at the 2022 American Society of Hematology (ASH) Annual Meeting,...
"AHOD1331 study - Bv-AVEPC approved for 2-year-olds and older with previously untreated high risk cHL "
On November 10, 2022, the FDA approved #brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric...
Assessing the value of systemic Therapy and radiation therapy in Stage I Nodal Marginal Zone Lymphoma
In a large Propensity score matched retrospective study was conducted to assess the value of systemic Therapy and radiation therapy...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
ECHELON-1 trial
The addition of #brentuximab_vedotin shows survival benefits in patients with previously untreated stage III or IV classic #Hodgkin’s_lymphoma. The ECHELON-1...
.png)